article thumbnail

Global Generic Drugs (Small Molecule Generics vs Biosimilars) Market Forecast & Opportunities, 2021-2026 by Application, Drug Delivery, Form, Source, Distribution Channel – ResearchAndMarkets.com

BioTech 365

Global Generic Drugs (Small Molecule Generics vs Biosimilars) Market Forecast & Opportunities, 2021-2026 by Application, Drug Delivery, Form, Source, Distribution Channel – ResearchAndMarkets.com Global Generic Drugs (Small Molecule Generics vs Biosimilars) Market Forecast & Opportunities, 2021-2026 by Application, Drug Delivery, … (..)

article thumbnail

Eli Lilly Partners with Amazon Pharmacy for Home Delivery of Drugs

XTalks

Amazon Pharmacy says it is focused on transparent pricing and affordability of both branded and generic drugs. It also introduced a feature that allows users to use coupons at checkout to get manufacturer discounts on brand name medications. If you want your company to be featured on Xtalks.com, please email ayeshar@xtalks.com.

Pharmacy 111
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Update: FDA clears first generic of AZ’s blockbuster Symbicort

pharmaphorum

Viatris (formerly Mylan) has become the first drugmaker to win full FDA approval for a generic version of AstraZeneca’s top-selling respiratory drug Symbicort, although launch plans remain uncertain for now. Symbicort brought in worldwide sales of $2.7 billion last year, with $1.1

article thumbnail

To List or Not to List; That is the Question – The FTC Signals the Potential for Greater Scrutiny of Patent Information Submissions to FDA

FDA Law Blog

The closest FDA has come is in a 2003 preamble noting that patents that claim finished dosage forms—which can include “metered aerosols, capsules, metered sprays, gels, and pre-filled drug delivery systems”—should be listed in the Orange Book, suggesting that a patent that claims both the drug substance and the delivery device should be listed.

Drugs 105
article thumbnail

XPhyto Announces Business Strategy and Milestones For 2021 Innovation to Impact

The Pharma Data

In 2020, XPhyto’s German subsidiary, Vektor Pharma TF GmbH (“Vektor”), a leader in the development of transdermal and sublingual drug formulations reported significant advancements in four therapeutic development programs. About XPhyto Therapeutics Corp. XPhyto Therapeutics Corp.

article thumbnail

XPhyto Announces Drug Formulation Strategy and 2021 Milestones Innovation to Impact

The Pharma Data

In 2020, XPhyto confirmed successful activation of its peptide-based biosensor program when delivered using Vektor’s sublingual drug delivery platform. Further, Vektor is currently engaged in the development of a sublingual drug formulation for a major European generic drug company.

Drugs 52
article thumbnail

RxPass, Amazon’s New Prescription Drug Program, Offers Common Meds for a Flat Fee of $5

XTalks

The list of available medicines includes about 50 generic drugs. Amazon Pharmacy’s growing initiatives in the space, including RxPass and its prescription delivery and price-comparison site through Amazon PillPack, will be posing a threat to traditional drugstore giants like CVS Health Corp (CVS.N)